How receptors mediate the entry of hepatitis B virus (HBV) into the target liver cells is poorly understood. Recently, human squamous cell carcinoma antigen 1 (SCCA1) has been found to mediate binding and internalization of HBV to liver-derived cell lines in vitro. In this report, we investigate if SCCA1 is able to function as an HBV receptor and mediate HBV entry into mouse liver. SCCA1 transgene under the control of Rous sarcoma virus promoter was constructed in a minicircle DNA vector that was delivered to NOD/SCID mouse liver using the hydrodynamic technique. Subsequently, HBV-positive human serum was injected intravenously. We demonstrated that approximately 30% of the mouse liver cells expressed a high level of recombined SCCA1 protein for at least 37 d. The HBV surface antigen was found to persist in mouse liver for up to 17 d. Furthermore, HBV genome also persisted in mouse liver, as determined by polymerase chain reaction, for up to 17 d, and in mouse circulation for 7 d. These results suggest that SCAA1 might serve as an HBV receptor or co-receptor and play an important role in mediating HBV entry into hepatocytes, although its role in human HBV infection remains to be determined.
Hepatitis B virus (HBV) is a human hepadnavirus that causes acute and chronic hepatitis and hepatocellular carcinoma [1] . As with other viral diseases, HBV infection is likely initiated by specific binding of the virus to cell membrane structures through one or several viral envelope proteins. HBV has not been propagated in established cell lines, and only humans and higher apes are susceptible to infection. HBV replication and cellular injury are largely confined to the liver, and the hepatocytes are considered the primary target cells for infection, whereas the significance of extrahepatic replication of HBV is not yet well understood.
The HBV envelope consists of three distinct coterminal proteins encoded by a single env gene. The domains of these proteins encoded by the pre-S region of the viral genome represent potential attachment sites of HBV to the hepatocyte, as pre-S1 and pre-S2 antibodies neutralize infectivity in vitro [2] as well as in experimental models [3] .
Although the viral structures involved in attachment to the target cell have been identified, the cellular receptors for HBV have not yet been determined and the biochemical events leading to intention remain unknown. As well as hepatocytes, many cells of nonhepatic origin, such as hematopoietic cells of the B lymphocyte lineage, peripheral blood lymphocytes, and even some simian virus 40-transformed cell lines, have receptors for the pre-S1 domain at amino acid 21−47 region [4] . The pre-S1 domain of the large envelope protein has a partial sequence homology with the Fc moiety of the α chain of immunoglobulin (Ig) A [5] , therefore a common receptor for the attachment of HBV and IgA to human liver cells has been proposed [6] . Interleukin 6, containing recognition sites for the pre-S1 domain, could mediate HBV-cell interaction [7] ; and the transferring receptor might also play a role in the binding of HBV to hepatocytes through the pre-S2 protein sequence, as this domain is involved in the binding of hepatitis B surface antigen (HBsAg) particles with T cells [8] . Another HBV binding factor (HBV-BF) was identified in normal human serum interacting with the pre-S1 and pre-S2 epitopes of the viral envelope located within the protein domain involved in the recognition of hepatocyte receptors. Monoclonal antibodies to HBV-BF recognized a membrane component of the normal human liver cells but were unreactive with the hepatocyte membrane of other species, and with that of the HepG2 cell line. The results suggested that HBV-BF represents a soluble fragment of the membrane component and might be related to the HBV receptor mediating the attachment of HBV to human liver cells [9] .
Squamous cell carcinoma antigen 1 (SCCA1), which is a member of the ovalbumin family of serine protease inhibitors, was found to play a major role in HBV infection and might be a new candidate for HBV-BF. By using tetravalent derivative chromatography from detergentsolubilized HepG2 plasma membranes, a 44 kDa HBV binding protein (HBV-BP) was found to closely correspond to human SCCA1. There are only three amino acid changes between them. Direct binding experiments confirmed the interaction of recombinant HBV-BP with the HBV pre-S1 domain. And in transfected cells, native HBV particle entry was enhanced. For example, HepG2 cells overexpressing HBV-BP after transfection with corresponding cDNA showed an increased virus binding capacity by two orders of magnitude compared with normal cells; and Chinese hamster ovary cells, which normally do not bind to HBV, acquired susceptibility to HBV binding after transfection. Both recombinant HBV-BP and antibodies to recombinant HBV-BP blocked virus binding and internalization in transfected cells as well as in primary human hepatocytes in a dose-dependent manner [10] . Although many candidates for the HBV receptor have been suggested in studies in vitro, none of them was proved in vivo that is much closer to the natural HBV infection in the human body.
In the present study, we get a special trangene mouse that expresses the HBV receptor candidate, the 44 kDa HBV-BP, in the liver cells by using a hydrodynamics-based intravenous injection procedure and a novel minicircle plasmid as vector. This novel and economical mouse model will be very useful in HBV receptor research.
Materials and Methods

Materials
Rabbit anti-SCCA1 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, USA). Rabbit anti-HBsAg antibody was from ViroStat (Portland, USA). X-gal was from TaKaRa Bio. (Kyoto, Japan). The SABC kit was from Boster Biological Technology (Wuhan, China). The infectant human serum (HBV-DNA + , 10 6 copies/ml) was provided by Prof. Ling LI (Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China). The HBV-DNA PCR detection kit was purchased from Da'an Gene Technology (Guangzhou, China). NOD/SCID mice were purchased from the Center of Experimental Animals (Sun Yat-Sen University). All other chemicals used were of analytical grade.
Plasmid
Minicircle-producing plasmid p2ΦC31 was a gift from Dr. M. A. KAY (Stanford University, Stanford, USA) [11] . SCCA1 cDNA was purchased from Open Biosystems (Huntsville, USA). p2ΦC31.SCCA1 was constructed by cloning SCCA1 under the control of RSV promoter into the XhoI site of plasmid p2Φ C31. p2Φ C31.LacZ was constructed by placing the bacterial β-galactosidase (LacZ) gene under the control of CMV promoter into the XhoI site of plasmid p2ΦC31. Minicircles encoding CMV-LacZ (MC.LacZ) and RSV-SCCA1 (MC.SCCA1) were prepared according to the procedure described by Chen et al. [11] . Regular plasmid DNA was purified by using the CsCldensity gradient centrifugation method and kept in saline at −20 ºC until use. Purity of plasmid DNA was checked by absorbency at 260 and 280 nm and by 2% agarose gel electrophoresis.
X-gal staining
To examine the site of transgene expression, two mice were given 2 ml saline containing 5 μg of pMC-LacZ plasmid DNA through the tail vein, using a 2.5 ml latexfree syringe with a 0.45×16 RW LB needle (Shuang Ge, Shanghai, China). The injection rate was kept at 0.4 ml/s. The location and level of LacZ gene expression in mouse liver was determined by the X-gal staining method. Tissue sections (5 μm thick) were made 24 h after plasmid injection, stained with X-gal for 2 h, then counterstained in Nuclear Fast Red (Boster Biological Technology) for 30 s. The positive cells showed blue staining in the cytoplasm or nucleus and the connective tissues were stained pink.
Immunohistochemistry evaluation for SCCA1
Two mice were killed on day 3, 7, 17, 27 and 37 after injection of pMC-SCCA1, respectively. Paraffin sections of liver were analyzed for the presence of SCCA1 by immunohistochemistry. For SCCA1 detection, rabbit polyclonal antibody SCCA1/2 (H-390) (Santa Cruz Biotechnology) was used at 1:200 dilution. Sections were incubated with primary antibody overnight at 4 ºC. The endogenous peroxidase activity was blocked with 3% hydrogen peroxide, then the slides were heated in 10 mM sodium citrate in a microwave oven to block nonspecific protein binding in normal goat serum. Biotinylated goat anti-rabbit IgG (Boster Biological Technology) was then added at room temperature for 20 min. Samples were incubated with avidin-peroxidase and stained with a mixture of 3,3'-diamino-benzidine tetrahydrochloride and hydrogen peroxide (Boster Biological Technology).
In each case of immunohistochemistry experiment, sections incubated with the appropriate non-immune IgG were used as the negative control. For antibody specificity confirmation, human skin specimens for SCCA1 were used as the positive control and the liver samples from a normal mouse were used as the negative control.
In each case, the semiquantitative immunoreactivity of SCCA1 was independently evaluated by two pathologists. In all immunohistochemical analyses, necrotic areas and edges of tissue sections were not included in the counting to avoid possible immunohistochemical false positivity.
In vivo transfection
Animals were divided into four groups. Group 1 (negative control 1, two mice): the mice did not receive injection.
Group 2 (negative control 2, two mice): the mice were injected through the tail vein with 5 μg pMC-SCCA1 in 2 ml saline, and killed 3 d later. Group 3 (negative control 3, 10 mice): the mice were injected through the tail vein with 2 ml saline. Twenty-four hours later the mice were injected through the tail vein with 0.3 ml of HBV-DNA + serum, and 1 d later the same quantity of serum was given to each mouse through the celiac artery. Two mice were killed on day 3, 7, 17, 27 and 37, respectively. Group 4 (experimental group, 10 mice): the mice were injected through the tail vein with 5 μg pMC-SCCA1 in 2 ml saline and 24 h later the mice were injected through the tail vein with 0.3 ml of HBV-DNA + serum. One day later the same quantity of serum was given to the mice through the celiac artery. Two mice were killed on day 3, 7, 17, 27 and 37, respectively.
For each group, the liver and serum samples were collected at appropriate times.
Immunohistochemistry detection for HBsAg
Liver sections from the four groups above were analyzed for the presence of HBsAg by immunohistochemistry. For HBsAg detection, rabbit anti-HBsAg antibody (ViroStat) was used as the primary antibody at 1:200 dilution. The protocols were the same as for SCCA1 detection.
Enzyme-linked immunosorbent assay (ELISA) for HBsAg in mouse serum
The collected mouse sera were tested for HBsAg using an ELISA kit and the AxSYM system (Abbott Diagnostics, Chicago, USA) according to the manufacturer's protocols.
PCR detection of HBV-DNA in mouse serum and liver
The collected mouse sera were tested for HBV-DNA using the HBV-DNA detection kit (Da'an) according to the protocols.
The genomic DNA was extracted from 200−300 mg mouse liver tissue. Five hundred microliters of 1×lysis buffer (40 mM NaCl, 10 mM Tris, pH 7.5, 1 mM EDTA) and 20 μl of RNase solution (10 mg/ml) was added to each pre-cooled tube. The live tissue was homogenized while keeping the tube in the pre-cooled heating-block and transferred to a 15 ml F2097 tube, then 3500 μl of 1×lysis buffer, 300 μl of 0.10% sodium dodecylsulfate and 1000 μl of proteinase K solution (2.0 mg/ml) were added. The mixture was incubated at 55 ºC for 2 h and at 37 ºC overnight with shaking. Ten microliters of 10 mg/ ml RNase was added, mixed and incubated at 55 ºC for 2 h with shaking. Two milliliters of saturated NaCl solution was added, mixed by pipetting up and down five times using a 5 ml pipetter, then centrifuged at 3500 g for 30 min using a clinical centrifuge. The supernatant was removed to a fresh tube, 1 ml of saturated NaCl solution was added, and the mixture was centrifuged for 30 min as above. The supernatant was removed to a fresh tube and two volumes of 100% ethanol was added. DNA will show up after mixing the solution by reversing the tube several times. The DNA was taken to a 1.5 ml Eppendorf tube, washed twice with 75% ethanol and centrifuged at 6000 g to remove as much ethanol as possible. The DNA was air dried at room temperature for 5 min, then 600 μl of TE buffer (1 mM EDTA, pH 8.0, 10 mM Tris-HCl) was added to dissolve it. Two microliters of the DNA solution was used as the template of following PCR. The mouse liver samples were tested for HBV-DNA using the HBV-DNA detection kit (Da'an) according to the protocols. Twelve microliters of samples was analyzed by 2.0% agarose gel electrophoresis. One day later the negative control PCR reaction was carried out with liver samples from a mouse injected with pMC-SCCA1 but not with infectant human serum. The positive control PCR http://www.abbs.info; www.blackwellpublishing.com/abbs reaction was carried out with 2 μl of positive DNA template solution provided with the kit.
Results
We used LacZ gene as the reporter gene to identify the site of transgene expression. Twenty four hours after infusion of 5 μg of pMC-LacZ plasmid DNA, the animals were killed and LacZ gene expression was assessed in the liver tissue. LacZ gene expression in the liver tissue seems restricted within certain areas as X-gal-positive cells are clustered around the central vein [ Fig. 1(A) ].
The pattern of SCCA1 transgene expression and the cell types that express SCCA1 protein were evaluated by immunohistochemical analysis [ Fig. 1(B,C) ]. Compared with the negative control, a number of cells in the liver tissue were stained positively by the SCCA1 antibody after injection of 5 μg pMC-SCCA1 plasmid into mice. The cells expressing SCCA1 are located around the central vein.
Positive cell counting was used to evaluate the persistence of SCCA1 gene expression. Table 1 shows that SCCA1 gene expression was persistent at a stable level for at least 37 d after transfection with the positive cell ratio being approximately 30%.
It is evident that no cell was detected to be positively immunoreactive for HBsAg in the liver of the mouse injected with infectant human serum only (Fig. 2) . The cells around the central vein and hepatic sinusoid, including the Kupffer cells, sinusoidal endothelial cells and some hepatocytes, were found to be positively immunoreactive up to day 17 of pMC-SCCA1 group. No positive cells were detected in the mice of day 27 and 37 of pMC-SCCA1 group.
The HBsAg qualitative ELISA analysis showed that the mouse serum on day 3 was positive and the others (day 7, 17, 27 and 37) were negative in the control group. In the experimental group, the mouse sera of day 3 and 7 were positive and the others (day 17, 27 and 37) were negative ( Table 2) .
Data in Fig. 3 show that HBV DNA was detected only in the mouse serum and liver tissue of day 3 of control group injected with infectant human serum and not injected with pMC-SCCA1 in advance. However, HBV DNA was found to be positive in the liver of day 3, 7 and 17 and in the mouse serum of day 3 and 7 injected with pMC-SCCA1 24 h before injection with infectant human serum. No HBV DNA was detected in the liver or serum of day 27 or 37. http://www.abbs.info; www.blackwellpublishing.com/abbs
Discussion
Due to its role in synthesizing many proteins and its involvement in numerous genetic and acquired diseases, the liver is an important target organ for gene transfer. A variety of vectors have been used for introducing genes into the liver, including recombinant retrovirus [12] , adenovirus [13] , adeno-associated virus [14] , and nonvirus vectors such as liposome [15] , cationic polymer [16] , and reconstituted chylomicron remnant [17] . Although significant progress has been made in the successful delivery of genes to the liver, many problems are associated with each of these methods. Retrovirus vector can generate long-term transgene expression, but partial hepatectomy or liver damage is usually required to stimulate cell division [18] . Adenoviral vector allows for high transferring efficiency, but gene expression lasts for a short period due to the host's immune response against viral protein [19] . Adeno-associated viral vectors produce long-term gene expression, but they can not deliver genes of a size more than 5.2 kb [20] . The current nonviral vectors suffer from the major limitation of low transfection efficiency.
To overcome these problems, Zhang et al. [21] explored the hydrodynamics-based procedure. Using this method, liver cells can be transfected with a foreign gene by rapid injection of a large volume of plasmid DNA solution. It was demonstrated that the liver was the only organ that expressed the transferred gene and the expression persisted for at least 6 months [22] . In our present study, by using this method we transferred the candidate HBV receptor gene SCCA1 into mouse liver, the target organ of HBV.
The loss of transgene expression has been a major obstacle to the development of nonviral vectors for the treatment of human diseases. Chen et al. [11] previously demonstrated that bacterial DNA linked to a mammalian expression cassette resulted in transcriptional silencing of the transgene in vivo. To develop a means to produce a robust DNA vector that is not silenced in vivo, they developed a phage ΦC31 integrase-mediated intramolecular recombination technology to prepare minicircle vector DNA devoid of the bacterial backbone. The authors reported that minicircle DNAs devoid of bacterial sequences expressed 45-and 560-fold more serum human factor IX and α1-antitrypsin, respectively, compared to standard plasmid DNAs transfected into mouse liver. Their data suggest that minicircles are capable of expressing high and persistent levels of therapeutic products in vivo and have a great potential to serve as episomal vectors for the treatment of a wide variety of diseases. The present data showed that mouse liver expressed a high level of In the control group, mice were injected with infectant human serum only. In the experimental group, mice were injected with pMC-SCCA1 24 h before injection with infectant human serum. The mouse serum was tested for HBsAg using an ELISA kit and an AxSYM system according to the manufacturers' protocols. S/N, the ratio of specimen to negative control. +, HBsAg positive (S/N≥2.10); −, HBsAg negative (S/N<2.10).
recombined SCCA1 protein at a detectable level under our experimental conditions for at least 37 d after injection. This HBV-BP transgene mouse would be a very useful animal model for the study of the function of SCCA1 involved in HBV binding and internalization in vivo.
Our data of the HBV study in this mouse model suggested that HBV can stay longer in the liver by intravenous injection of pMC-SCCA1 using a hydrodynamics-based procedure. Although the liver tissues of the 3, 7 and 17 d groups showed positive in the immunohistochemical examination and HBV-DNA PCR test, there was no HBV-DNA detected in the 27 or 37 d groups [ Fig. 2(G−L) and Fig. 3 ]. These findings suggested that this protein in vivo might help HBV binding to the mouse liver cells that express this protein, and that SCCA1 might serve as an HBV receptor or co-receptor and play an important role in mediating HBV entry to hepatocytes. However, its role in human HBV infection remains to be further determined.
The sinusoidal endothelial and Kupffer cells near the hepatic sinusoid were found to be strongly positive in the immunohistochemical test [ Fig. 2(H−J) ]. This suggests that the cells might play an important role in HBV clearance as the first defence against HBV infection, and this function deficiency might give HBV more access to hepatocytes.
In summary, our data in this report show that the longterm expression of the suspected HBV receptor gene can be achieved in a mouse model by simple tail vein injection of the minicircle plasmid using a hydrodynamics-based procedure. This method gives access to the HBV receptor research, and our studies proved in vivo that this HBV-BP can extend its retention of HBV in mouse liver. However, there are still other factors involved in HBV infection and further quantitive research on this animal model is needed. Edited by Yuan WANG
